Acute Myeloid Leukemia Market, Application, by gross margin and forecast to 2023
Global Acute Myeloid Leukemia Market Information; by Disease Type (Myeloblastic, Promyeloctic, Myelomonocytic, Monocytic, Erythroleukemia, Megakaryocytic); by Treatment (Chemotherapy (Induction, Post Remission), Hematopoietic Stem Cell Transplantation) - Forecast to 2023
Market Highlights
Market Research Futures (MRFR) report on the global acute myeloid leukemia (AML) treatment is expected to grow at a moderate CAGR of 5.3% over the forecast period of 2017 to 2023 and culminate in a value above USD 1 Bn by the end of the assessment period. This type of cancer is comparatively rare and progresses at a rapid pace thus creating significant demand for effective treatment and diagnostic options.
Increasing diagnoses of AML are due to exposure to carcinogenics which are present everywhere. Changing lifestyles have given rise to unhealthy habits which lead to cancer. AML can also be passed genetically, and increased prevalences of cancer combined with the growing population drive the market. Other key factors of note which are affecting the Acute Myeloid Leukemia Market include improving reimbursement policies, and increasing number of cancer hospitals staffed with specialists to specifically treat cancers like AML. Supportive funding for research and development of treatment for this swiftly progressing diseases is expected to offer various opportunities for growth. Awareness regarding actual myeloid leukemia has been observed to be increasing and is likely to increase diagnoses and lead to growth over the forecast period. However, the side effects associated with drugs used for treatment currently and the availability of effective medication are challenging the growth of the market.
Acute Myeloid Leukemia Treatment Market Segmentation
The global Acute Myeloid Leukemia Market is segmented on the basis of disease type, treatment, and region. By disease type, the market is segmented into promyelocytic, myeloblastic, myelomonocytic, monocytic, megakaryocytic and erythroleukemia.
By treatment, the market is segmented into chemotherapy and hematopoietic stem cell transplantation. The chemotherapy segment is further segmented into post remission and induction.
The regional segmentation of the AML treatment market divides the globe into North America, Europe, Asia Pacific and the Middle East and Africa.
Acute Myeloid Leukemia Treatment Market Key Players
The competitive analysis of the global AML market reveals key strategies used by various leading market players. Prominent players included in the report are Ambit Biosciences Corporation, Novartis AG, Sanofi, Cyclacel Pharmaceuticals Inc., Bristol Myers Squibb, Celgene Corporation, Johnson & Johnson, and Pfizer Inc.
GET FULL REPORT @ https://www.marketresearchfuture.com/reports/acute-myeloid-leukemia-treatment-market-3223
More Healthcare Related Reports
Global Population Health Management Market
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
